Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM6A | O15550 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24292359 | 0.83 | C1R (0.64) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL171055 | 0.82 | TOP2A (0.62) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL29504749 | 0.82 | TOP2A (0.62) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL12854009 | 0.80 | TOP2A (0.60) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL7243710 | 0.78 | C1R (0.74) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL27269424 | 0.78 | KDM4E (0.50) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL29531707 | 0.78 | NPC1 (0.69) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL824375 | 0.78 | NPC1 (0.69) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL4159029 | 0.77 | NPC1 (0.67) | ALDH1A1KDM4EHPGDMAPTUSP2 | |
| SCHEMBL12794310 | 0.77 | MAPT (0.59) | ALDH1A1KDM4EHPGDMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| CN-1154852-C | Self-scintillating sheet material for radioactive species analysis | 3M | 2004-06-23 | — | — | CN | disclosed |
| CN-1279767-A | Self-scintillating sheet material for radioactive species analysis | MINNESOTA MINING & MFG (US) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | ALDH1A1 1659/4885KDM4E 2901/4885HPGD 1603/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | ALDH1A1 1920/4885KDM4E 3486/4885HPGD 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.